A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. [electronic resource]
Producer: 20060417Description: 1221-8 p. digitalISSN:- 1078-0432
- Adult
- Aged
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents -- administration & dosage
- Area Under Curve
- Bone Neoplasms -- prevention & control
- Bone and Bones -- drug effects
- Breast Neoplasms -- drug therapy
- Carrier Proteins -- antagonists & inhibitors
- Collagen -- blood
- Collagen Type I
- Creatinine -- urine
- Denosumab
- Diphosphonates -- administration & dosage
- Double-Blind Method
- Female
- Humans
- Injections, Intravenous
- Injections, Subcutaneous
- Male
- Membrane Glycoproteins -- antagonists & inhibitors
- Middle Aged
- Multiple Myeloma -- drug therapy
- Pamidronate
- Peptides -- blood
- RANK Ligand
- Receptor Activator of Nuclear Factor-kappa B
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.